BioDelivery Sciences International (NASDAQ:BDSI) released its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.04, Morningstar.com reports. The company had revenue of $14.16 million during the quarter, compared to analysts’ expectations of $14.21 million. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 278.79%.

Shares of BDSI traded up $0.09 during mid-day trading on Friday, hitting $3.78. The company’s stock had a trading volume of 688,322 shares, compared to its average volume of 731,159. BioDelivery Sciences International has a 52-week low of $1.70 and a 52-week high of $4.14. The stock has a market capitalization of $224.54 million, a PE ratio of -9.69 and a beta of 0.09. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.90 and a current ratio of 3.16.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $3.84, for a total value of $30,720.00. Following the completion of the sale, the director now owns 522,187 shares of the company’s stock, valued at approximately $2,005,198.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 151,039 shares of the company’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the sale, the director now directly owns 520,482 shares of the company’s stock, valued at approximately $1,478,168.88. The disclosure for this sale can be found here. Insiders sold a total of 175,039 shares of company stock valued at $503,991 in the last ninety days. Corporate insiders own 13.26% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of BDSI. Bank of Montreal Can bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $138,000. Royce & Associates LP raised its stake in shares of BioDelivery Sciences International by 19.1% during the 2nd quarter. Royce & Associates LP now owns 2,200,800 shares of the specialty pharmaceutical company’s stock worth $6,492,000 after acquiring an additional 352,200 shares in the last quarter. BlackRock Inc. raised its stake in shares of BioDelivery Sciences International by 2.7% during the 2nd quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock worth $3,512,000 after acquiring an additional 30,991 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $148,000. Finally, Cortina Asset Management LLC bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $5,629,000. Hedge funds and other institutional investors own 46.10% of the company’s stock.

BDSI has been the subject of several research reports. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Monday, July 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $4.50 price objective on shares of BioDelivery Sciences International in a research report on Thursday, August 9th. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research report on Friday, August 10th. Finally, Janney Montgomery Scott upped their price target on shares of BioDelivery Sciences International to $5.00 and gave the stock a “buy” rating in a research report on Friday, November 2nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $4.54.

ILLEGAL ACTIVITY WARNING: “BioDelivery Sciences International (BDSI) Issues Quarterly Earnings Results” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/10/biodelivery-sciences-international-bdsi-issues-quarterly-earnings-results.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: Short Selling – Explanation For Shorting Stocks

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.